Bisphosphonate conjugation for bone specific drug targeting
Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bone remains an important goal for achieving effecti...
Main Authors: | Kristen B. Farrell, Alexander Karpeisky, Douglas H. Thamm, Shawn Zinnen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-12-01
|
Series: | Bone Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S235218721830041X |
Similar Items
-
Carbon Nanotubes as Biosensors for Releasing Conjugated Bisphosphonates–Metal Ions in Bone Tissue: Targeted Drug Delivery through the DFT Method
by: Fatemeh Mollaamin, et al.
Published: (2023-06-01) -
Bisphosphonate conjugation enhances the bone-specificity of NELL-1-based systemic therapy for spaceflight-induced bone loss in mice
by: Pin Ha, et al.
Published: (2023-09-01) -
Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid
by: M. Meckel, et al.
Published: (2016-09-01) -
Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer
by: Zintle Mbese, et al.
Published: (2021-06-01) -
Bisphosphonates and bone quality.
by: Pazianas, M, et al.
Published: (2014)